MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
As of June 30, 2022, cash and cash equivalents were EUR 38.4 million1 Revenues of EUR 0.2 million1 in Q2 2022 LYON, France–(BUSINESS WIRE)–$MAAT—MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today … [Read more…]